Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
July 25, 2025 16:05 ET | Source: Celcuity Inc. MINNEAPOLIS, July 25,…
Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted…
Bridge Capture enables sensitive, scalable liquid biopsy in colorectal cancer pilot
Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from…
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:…
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…
‘Haven of Hope’ – Shelter Home for Underprivileged Cancer Patients Inaugurated in Kochi
The 'Haven of Hope' building, built under South Indian Bank's CSR initiative…
Trusted Oncology Guidelines Get a Digital Makeover: National Comprehensive Cancer Network Launches NCCN Guidelines Navigator
The new interactive guideline tool represents a major format change for gold-standard…
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic…
The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer
Two pioneering scientists received The Brain Prize 2025 for their discoveries that…
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer…
